Jul 09, 2019
Orexo Prepays Part of the Corporate Bond Loan
Jun 28, 2019
Number of Shares and Votes in Orexo
Jun 12, 2019
Issue and Repurchase of Class C Shares
May 31, 2019
Number of Shares and Votes in Orexo
May 17, 2019
Orexo's Closest Upcoming Presentations at Conferences
May 02, 2019
Orexo: Interim Report Q1 2019
Apr 26, 2019
Issues of Shares Following the Vesting of 2016/2019 Incentive Plan
Apr 11, 2019
Report from Orexo AB's Annual General Meeting
Mar 29, 2019
District Court of Delaware Rules that Actavis does not Infringe with their Suboxone® and Subutex® Generics
Mar 21, 2019
Orexo Publishes the Annual Report for 2018
Feb 28, 2019
Number of Shares and Votes in Orexo
Jan 11, 2019
Actavis Infringes Orexo's Long Term Zubsolv® U.S. Patent ´330
Jan 07, 2019
Positive Results From Human PK Study Assessing Orexo's New Intranasal Naloxone Formulations for Opioid Overdose Reversal
Dec 13, 2018
Orexo Regains Rights to Zubsolv® in all Countries Outside the US
Dec 06, 2018
Orexo Hosts Capital Markets Day Today in Stockholm, Sweden
Nov 30, 2018
US Court of Appeals Denies Actavis's Petition for Rehearing Regarding Validity of the Zubsolv® Patent
Nov 08, 2018
Orexo to Host a Capital Markets Day on Dec. 6 With the US President´s Former Advisor as Keynote Speaker
Oct 25, 2018
Orexo - Interim Report Q3 2018
Oct 24, 2018
Save the Date: Orexo to Host Capital Markets Day on Dec. 6 With the US President´s Former Advisor as Key Note Speaker
Oct 24, 2018
Orexo Appoints Joseph DeFeo as New CFO